Antioxidant effects of statins in patients with Atherosclerotic Cerebrovascular Disease

Journal of Clinical Neurology (Korea)

Volumn 10, Issue 2, 2014, Pages 140-147

  Moon, Gyeong Joon ^a,b   Kim, Suk Jae ^a   Cho, Yeon Hee ^b   Ryoo, Sookyung ^a   Bangc, Oh Young ^a,c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Samsung Advanced Institute of Technology (SAIT)   (South Korea)

Author keywords

Atherosclerosis; Cholesterol; Ischemic stroke; Oxidative stress; Statin

Indexed keywords

EID: 84897556398     PISSN: 17386586     EISSN: 20055013     Source Type: Journal    
DOI: 10.3988/jcn.2014.10.2.140     Document Type: Article

References (38)

1. Kelly PJ, Morrow JD, Ning M, Koroshetz W, Lo EH, Terry E, et al. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke 2008;39:100-104.
2. Sánchez-Moreno C, Dashe JF, Scott T, Thaler D, Folstein MF, Martin A. Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke. Stroke 2004; 35:163-168.
3. Leinonen JS, Ahonen JP, Lönnrot K, Jehkonen M, Dastidar P, Molnár G, et al. Low plasma antioxidant activity is associated with high lesion volume and neurological impairment in stroke. Stroke 2000;31:33-39.
4. Floyd RA, Hensley K. Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 2002;23: 795-807.
5. Tuñón J, Martín-Ventura JL, Blanco-Colio LM, Egido J. Mechanisms of action of statins in stroke. Expert Opin Ther Targets 2007;11:273- 278.
6. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559.
7. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359: 2195-2207.
8. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008;39:1647-1652.
9. Bang OY, Ovbiagele B, Liebeskind DS, Restrepo L, Yoon SR, Saver JL. Clinical determinants of infarct pattern subtypes in large vessel atherosclerotic stroke. J Neurol 2009;256:591-599.
10. Hennerici MG. Report of the 20th European Stroke Conference, Hamburg, May 24-27, 2011. Cerebrovasc Dis 2011;32:589-613.
11. LaRosa JC. Pleiotropic effects of statins and their clinical significance. Am J Cardiol 2001;88:291-293.
12. Lima JA, Desai MY, Steen H, Warren WP, Gautam S, Lai S. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 2004;110: 2336-2341.
13. Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol 2005;58:688-697.
14. Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 1994;233:346-357.
15. Nagayama T, Lan J, Henshall DC, Chen D, O'Horo C, Simon RP, et al. Induction of oxidative DNA damage in the peri-infarct region after permanent focal cerebral ischemia. J Neurochem 2000;75:1716-1728.
16. Moon GJ, Shin DH, Im DS, Bang OY, Nam HS, Lee JH, et al. Identification of oxidized serum albumin in the cerebrospinal fluid of ischaemic stroke patients. Eur J Neurol 2011;18:1151-1158.
17. de Nigris F, Lerman A, Ignarro LJ, Williams-Ignarro S, Sica V, Baker AH, et al. Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis. Trends Mol Med 2003;9:351-359.
18. Corrêa Mde C, Maldonado P, da Rosa CS, Lunkes G, Lunkes DS, Kaizer RR, et al. Oxidative stress and erythrocyte acetylcholinesterase (AChE) in hypertensive and ischemic patients of both acute and chronic stages. Biomed Pharmacother 2008;62:317-324.
19. Demirkaya S, Topcuoglu MA, Aydin A, Ulas UH, Isimer AI, Vural O. Malondialdehyde, glutathione peroxidase and superoxide dismutase in peripheral blood erythrocytes of patients with acute cerebral ischemia. Eur J Neurol 2001;8:43-51.
20. Polidori MC, Cherubini A, Stahl W, Senin U, Sies H, Mecocci P. Plasma carotenoid and malondialdehyde levels in ischemic stroke patients: relationship to early outcome. Free Radic Res 2002;36:265-268.
21. Alexandrova ML, Bochev PG, Markova VI, Bechev BG, Popova MA, Danovska MP, et al. Oxidative stress in the chronic phase after stroke. Redox Rep 2003;8:169-176.
22. Ishigaki Y, Katagiri H, Gao J, Yamada T, Imai J, Uno K, et al. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 2008;118:75-83.
23. Gil-Núñez AC, Villanueva JA. Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors. Cerebrovasc Dis 2001;11 Suppl 1:85-95.
24. Uno M, Harada M, Takimoto O, Kitazato KT, Suzue A, Yoneda K, et al. Elevation of plasma oxidized LDL in acute stroke patients is associated with ischemic lesions depicted by DWI and predictive of infarct enlargement. Neurol Res 2005;27:94-102.
25. Ky B, Burke A, Tsimikas S, Wolfe ML, Tadesse MG, Szapary PO, et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol 2008; 51:1653-1662.
26. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 2004;109(21 Suppl 1):II34-II41.
27. Skrha J, Stulc T, Hilgertová J, Weiserová H, Kvasnicka J, Ceska R. Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. Eur J Pharmacol 2004;493:183-189.
28. Molcányiová A, Stancáková A, Javorský M, Tkác I. Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia. Pharmacol Res 2006;54:203-207.
29. Burcham PC, Kuhan YT. Introduction of carbonyl groups into proteins by the lipid peroxidation product, malondialdehyde. Biochem Biophys Res Commun 1996;220:996-1001.
30. Chang CY, Lai YC, Cheng TJ, Lau MT, Hu ML. Plasma levels of antioxidant vitamins, selenium, total sulfhydryl groups and oxidative products in ischemic-stroke patients as compared to matched controls in Taiwan. Free Radic Res 1998;28:15-24.
31. Liu H, Uno M, Kitazato KT, Suzue A, Manabe S, Yamasaki H, et al. Peripheral oxidative biomarkers constitute a valuable indicator of the severity of oxidative brain damage in acute cerebral infarction. Brain Res 2004;1025:43-50.
32. Li S, Zheng J, Carmichael ST. Increased oxidative protein and DNA damage but decreased stress response in the aged brain following experimental stroke. Neurobiol Dis 2005;18:432-440.
33. Aydin S, Uzun H, Sozer V, Altug T. Effects of atorvastatin therapy on protein oxidation and oxidative DNA damage in hypercholesterolemic rabbits. Pharmacol Res 2009;59:242-247.
34. Blakeman DP, Ryan TP, Jolly RA, Petry TW. Protein oxidation: examination of potential lipid-independent mechanisms for protein carbonyl formation. J Biochem Mol Toxicol 1998;12:185-190.
35. Cano CP, Bermúdez VP, Atencio HE, Medina MT, Anilsa A, Souki A, et al. Increased serum malondialdehyde and decreased nitric oxide within 24 hours of thrombotic stroke onset. Am J Ther 2003;10:473- 476.
36. Zimmermann C, Winnefeld K, Streck S, Roskos M, Haberl RL. Antioxidant status in acute stroke patients and patients at stroke risk. Eur Neurol 2004;51:157-161.
37. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-924.
38. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004;173:1-12.